ALK corp fact sheet -no tech chart 08-22-14.indd

Alkermes plc is a fully
integrated, global biopharmaceutical company
focused on developing
innovative medicines
that address the unmet
needs and challenges
of people living with
serious, chronic diseases.
At Alkermes plc, our employees consistently strive to provide physicians and
patients with better treatment options. Through our scientific expertise, proprietary
technologies and global resources, we are uniquely positioned to continue building a
portfolio of medicines for major clinical conditions with a focus on central nervous
system (CNS) disorders.
Our success to date is evident from our more than 20 marketed drugs, including breakthrough treatments in major diseases, such as schizophrenia, addiction, diabetes and
multiple sclerosis. Beyond our commercial products, we have a promising pipeline of
proprietary drug candidates, many in late-stage development. Both our commercialized
products and rich pipeline demonstrate our leadership in drug development for CNS
diseases, a therapeutic area where we have established expertise and a promise for
delivering new treatments.
KEY COMMERCIAL PRODUCTS
WEBSITE
www.alkermes.com
TICKER SYMBOL
NASDAQ: ALKS
HEADQUARTERS
Connaught House
1 Burlington Road
Dublin 4, Ireland
+353 1 772 8000
EMPLOYEES
Approximately 1,250 WW
CONTACTS
Rebecca Peterson
Senior Vice President,
Corporate Communications
Voice: +1 781 609 6378
Blair Jackson
Vice President,
Business Development
Voice: +1 781 609 6594
Our diverse portfolio of more than 20 commercial
products reflects our years of experience in
developing innovative and patient-inspired
solutions. Among these, five key commercial
products are the drivers to propel our growth.
AMPYRA® (dalfampridine) is a twice-daily, controlled-release tablet indicated as a treatment to
improve walking in patients with multiple sclerosis.
AMPYRA is approved in the U.S. where it is
marketed by Acorda Therapeutics, Inc. Biogen Idec
holds the rights to develop and commercialize
the medication in all markets outside the U.S.,
where it is sold under the trade name FAMPYRA®.
BYDUREON® (exenatide extended-release
for injectable suspension) is the first and
only once-weekly therapy for the treatment of
type 2 diabetes. BYDUREON is an extendedrelease injectable suspension of exenatide – the
same active ingredient in BYETTA®. BYDUREON is
marketed in the U.S. and EU by AstraZeneca.
INVEGA® SUSTENNA® (paliperidone palmitate)
is a once-monthly injectable form of paliperidone
(INVEGA®) indicated for the treatment of
schizophrenia. Janssen Pharmaceuticals, Inc.
markets INVEGA SUSTENNA, which is
commercialized under the trade name XEPLION®
in the EU.
RISPERDAL® CONSTA® (risperidone LongActing Injection) is a long-acting injectable form
of Janssen’s schizophrenia drug RISPERDAL®
(risperidone). It is administered once every two
weeks, rather than daily, for the management of
schizophrenia and bipolar I disorder. RISPERDAL
CONSTA is commercialized by Janssen in more
than 90 countries, including the U.S., the UK,
Japan and Germany.
VIVITROL® (naltrexone for extended-release
injectable suspension) is an extended-release
injectable formulation of naltrexone. It is the
first and only non-narcotic, non-addictive, oncemonthly medication for both alcohol and opioid
dependence. Designed for once-monthly dosing,
VIVITROL eliminates the need for patients to
make a daily decision about taking their medicine.
Alkermes commercializes VIVITROL in the U.S.
Janssen Pharmaceuticals is responsible for the
commercialization of VIVITROL in Russia and
the CIS.
CLINICAL DEVELOPMENT PROGRAMS
At Alkermes plc, we approach the development of new therapeutics with a thoughtful focus on patients’ real-world needs. We are
committed to providing patients and caregivers with medicines that offer benefits in terms of safety, efficacy and ultimately, improved
health outcomes. This is illustrated by our focused and growing proprietary and partnered pipeline.
Preclinical
CANDIDATE
Phase 1
Phase 2
Phase 3
FDA Review
Aripiprazole Lauroxil (Schizophrenia)
INVEGA SUSTENNA 3-month (Schizophrenia)
Exenatide Once Weekly Suspension (Type 2 Diabetes)
ALKS 5461 (Major Depressive Disorder)
Exenatide Once Monthly (Type 2 Diabetes)
ALKS 3831 (Schizophrenia)
ALKS 8700 (Multiple Sclerosis)
ALKS 7106 (Pain)
RDB 1419 (Cancer)
LEADERSHIP TEAM
GLOBAL PRESENCE
RICHARD F. POPS
Chairman and
Chief Executive Officer
SHANE COOKE
President
KATHRYN L. BIBERSTEIN
Senior Vice President, Chief Legal
Officer and Chief Compliance Officer,
and Secretary Alkermes plc
MADELINE D. COFFIN
Vice President, Human Resources
ELLIOT W. EHRICH, M.D.
Senior Vice President, Research
and Development, and Chief
Medical Officer
JAMES M. FRATES
Alkermes Corporate Headquarters
Connaught House
1 Burlington Road
Dublin 4, Ireland
+353 1 772 8000
Athlone, Ireland Facility
Monksland, Athlone
Co Westmeath, Ireland
+353 90 649 5000
Gainesville, Georgia Facility
1300 Gould Drive
Gainesville, GA 30504
+1 770 531 8100
Wilmington, Ohio Facility
265 Olinger Circle
Wilmington, OH 45177
+1 937 382 5642
Waltham, Massachusetts Facility
852 Winter Street
Waltham, MA 02451
+1 781 609 6000
Senior Vice President,
Chief Financial Officer
GEORGIANNA HARRIS, Ph.D.
Vice President, Regulatory Affairs
BLAIR C. JACKSON
Vice President, Business
Development
MICHAEL J. LANDINE
Senior Vice President,
Corporate Development
PETER NORMAN
Vice President,
Government Policy and Affairs
REBECCA J. PETERSON
Senior Vice President,
Corporate Communications
GORDON G. PUGH
Senior Vice President,
Chief Operating Officer
and Chief Risk Officer
SRDJAN STANKOVIC, M.D.
Senior Vice President,
Clinical Development
and Medical Affairs
MARK P. STEJBACH
Senior Vice President,
Chief Commercial Officer
AMPYRA® and FAMPYRA® are registered trademarks of Acorda Therapeutics, Inc. BYDUREON® and BYETTA® are registered trademarks of Amylin Pharmaceuticals, LLC
and AstraZeneca Pharmaceuticals LP. RISPERDAL®, RISPERDAL® CONSTA®, INVEGA® and INVEGA® SUSTENNA® are registered trademarks of Janssen Pharmaceuticals,
Inc. XEPLION® is a registered trademark of Johnson & Johnson Corporation. VIVITROL® is a registered trademark of Alkermes, Inc.
Rev: Aug 2014